Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese market.
Under the partnership that will enable Lupin to expand footprint in China, SUP will obtain regulatory approvals for selling Tiotropium DPI in China. Lupin will be the marketing authorisation holder and responsible for manufacturing of the product.
Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. Their partnership comes in backdrop of increasing prevalence of respiratory conditions, Lupin said in a release on Monday.
“This partnership demonstrates our commitment to developing critical products for the treatment of respiratory diseases such as COPD and establishing our leadership in the global respiratory health sector,” Lupin’s President of Corporate Development Fabrice Egros said.
SUP president Wang Li said “by bringing more efficient and superior products to market, we aim to make significant breakthroughs in respiratory disease treatment in China, allowing more patients to benefit from international high-quality and innovative products and enjoy respiratory health.”
Lupin shares closed with a gain of less than 1% on the BSE at ₹2,010.55 each on Monday.
Published – June 16, 2025 08:45 pm IST
Source link
